Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-101 (SynphaTec)
- Development stage
- Unknown
- Lead developer
- Synphatec
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SP-101 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist under development by Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. for the treatment of major depressive disorder (MDD). Administered via intravenous infusion, SP-101 is designed to modulate glutamatergic signaling, a pathway implicated in the rapid relief of depressive symptoms. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetic profile in healthy adult volunteers. Like other NMDA receptor antagonists, SP-101 aims to provide a rapid-acting therapeutic effect for patients with depression who may not respond to traditional monoaminergic antidepressants.
- Other names
- SP-101 injectionSP101 injectionSP 101 injection
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on SP-101 (SynphaTec).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-101 (SynphaTec).